Key result
High remnant cholesterol linked to ~2.9-fold higher recurrent cardiovascular events in post-ACS patients.
Why the study?
Patients remain at high risk of recurrent cardiovascular events after ACS despite statin therapy, and triglyceride-rich lipoproteins influence this residual risk. This study examined the predictive value of remnant lipoprotein levels for secondary cardiovascular events in statin-treated post-ACS patients.
Cohort (n=190)
Single-blind
No
Answers are grounded in this paper and cite their sources.
May identify residual risk in statin-treated post-ACS patients; hypothesis-generating and should not yet change practice.
BACKGROUND: After acute coronary syndrome (ACS), there is a high risk of recurrent cardiovascular events. Triglyceride-rich lipoproteins influence residual cardiovascular risk in patients taking statin. This study examined the predictive value of remnant lipoprotein level for secondary cardiovascular events in patients treated with statins after ACS. METHODS AND RESULTS: A total of 190 patients treated with statins after ACS were enrolled in the study. The serum level of remnant lipoproteins (remnant-like lipoprotein particle cholesterol; RLP-C) was measured using an immunoseparation method. All the patients were followed prospectively for a maximum period of 70 months or until the occurrence of one of the following events: cardiac death, non-fatal myocardial infarction, unstable angina requiring unplanned coronary revascularization, or ischemic stroke. During the follow-up period, 42 patients had a secondary event. Multivariate Cox analysis showed that a high level of RLP-C (≥5.4 mg/dl; determined on receiver operating characteristic curve analysis) was a significant risk factor for secondary events, independent of conventional risk factors (hazard ratio, 2.94; 95% confidence interval: 1.40-6.18; P<0.01). The addition of high RLP-C to traditional risk factors enhanced net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI, 0.66, P=0.0003; and IDI, 0.08, P=0.0002). CONCLUSIONS: RLP-C is useful for risk assessment of secondary cardiovascular events in patients treated with statins after ACS.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2014) conducted a cohort in Acute coronary syndrome on statin therapy (n=190). High remnant-like lipoprotein particle cholesterol (RLP-C ≥5.4 mg/dl) vs. Low remnant-like lipoprotein particle cholesterol (RLP-C <5.4 mg/dl) was evaluated on Composite of secondary cardiovascular events (cardiac death, non-fatal myocardial infarction, refractory unstable angina requiring unplanned coronary revascularization, and ischemic stroke) (HR 2.94, 95% CI 1.40-6.18, p=<0.01). High remnant lipoprotein cholesterol independently predicted recurrent cardiovascular events in statin-treated post-ACS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: